연구동향 분석
박사

자기공명 혈관조영 검사에서 부작용 저감을 위한 최적 조영제 농도 = A study on optimal concentration of GBCA to reduce adverse effect in Magnetic Resonance Angiography

최관우 2015년

논문상세정보
    • 저자 최관우
    • 형태사항 삽도: vii, 66 p.: 26 cm
    • 일반주기 권두 국문요지, 권말 Abstract 수록, 지도교수: 송재철, 참고문헌: p. 56-63
    • 학위논문사항 학위논문(박사)-, 한양대학교 대학원, 2015. 8, 보건학과
    • 발행지 서울
    • 언어 kor
    • 출판년 2015
    • 발행사항 한양대학교 대학원
    • 주제어 혈액학
    유사주제 논문( 2)
인용/피인용
' 자기공명 혈관조영 검사에서 부작용 저감을 위한 최적 조영제 농도 = A study on optimal concentration of GBCA to reduce adverse effect in Magnetic Resonance Angiography' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 혈액학
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
3 0

0.0%

' 자기공명 혈관조영 검사에서 부작용 저감을 위한 최적 조영제 농도 = A study on optimal concentration of GBCA to reduce adverse effect in Magnetic Resonance Angiography' 의 참고문헌

  • 희석률에 따른 조영증강 자기공명혈관조영검사의 신호강도 평가
    서성미 손순룡 조영제 최관우 한국산학기술학회논문지, ;15(8):5124-5130 [2014]
  • 혈류에 의한 조영제 peak time의 산출에 관한 연구
    손순룡 이호범 최관우 한국산학기술학회논문지, ;14(5):2315-2321 [2013]
  • 한국소비자원
    알레르기 유발빈도 보고서 [2010]
  • 표적 자기 공명 영상 진단을 위한 이중 기능성 가돌리늄 착물
    남기수 경북대학교대학원 박사학위논문 [2014]
  • 컴퓨터 단층촬영(Computed Tomography)에 사용되는 조영제의 부작용 발생에대한 분석, 울산대학교 산업대학원
    권기수 석사학위논문 [2004]
  • 집적 정점시간에 미치는 영향 인자 분석에 관한 연구
    손순룡 조영제 한양대학교 대학원 박사학위논문 [2013]
  • 조영증강검사 시 생체 요인을 이용한 조영제 peak time에 관한 연구
    김윤신 민정환 서성미 손순룡 유병규 이종석 최관우 한국산학기술학회논문지, ;14(2):786-792 [2013]
  • 자기공명영상조영제(MR Contrast Media)
    서진석 대한자기공명의과학회, ;85-94 [1997]
  • 식품의약품안전처
    CT/MRI 조영제 부작용 사례보고 현황 [2014]
  • 식품의약품안전처
    의약품 안전성 서한(가돌리늄 함유 조영제) [2010]
  • 대한자기공명의과학회, 자기공명영상학
    일조각, :316-326 [2008]
  • 가돌리늄(GD)
    박준우 http://navercast.naver.com/contents.nhn?rid=44&contents_id=17034 [2012]
  • http://terms
    박문각 조영제 naver.com/entry.nhn?docId=7&cid=43667&categoryId=43667, 2015 [2079]
  • de Campos RO, Heredia V, Ramalho M, De Toni MS, Lugo-Somolinos A, Fuller ER3rd, Semelka RC, Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine forabdominal MRI in patients at risk for nephrogenic systemic fibrosis:preliminary observations, AJR Am J Roentgenol, 2011;196(3):545-552.
  • Zou Z, Ma L, Nephrogenic systemic fibrosis: review of 408 biopsy-confirmedcases, Indian J Dermatol, 2011;56(1):65-73.
  • Wang YX, Hussain SM, Krestin GP, Superparamagnetic iron oxide contrast agents:physicochemical characteristics and applications in MR imaging, Eur Radiol,2001;11(11):2319-2331.
  • Vogler H, Platzek J, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Raduchel B,Press WR, Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging, Eur J Radiol, 1995;21(1):1-10.
  • Tweedle MF, The ProHance story: the making of a novel MRI contrast agent, EurRadiol, 1997;7(5):225-230.
  • Tweedle MF, Physicochemical properties of gadoteridol and other magneticresonance contrast agents, Invest Radiol, 1992;27(1):2-6.
  • Thomsen HS, Nephrogenic systemic fibrosis: history and epidemiology, RadiolClin North Am, 2009;47(5):827-831.
  • Thomsen HS, Morcos SK, Almen T, Bellin MF, Bertolotto M, Bongartz G, Clement O,Leander P, Heinz-Peer G, Reimer P, Stacul F, van der Molen A, Webb JA,Nephrogenic systemic fibrosis and gadolinium-based contrast media: updatedESUR Contrast Medium Safety Committee guidelines, Eur Radiol, 2013;23(2):307-318.
  • Thakral C, Abraham JL, Nephrogenic systemic fibrosis: histology and gadoliniumdetection, Radiol Clin North Am, 2009;47(5):841-853.
  • Song KD, Kim SH, Lee J, Kang KA, Kim J, Yoo H, Half-dose gadoxetic acidenhancedliver magnetic resonance imaging in patients at risk for nephrogenicsystemic fibrosis, Eur J Radiol, 2015;84(3):378-383.
  • Shellock FG, Spinazzi A, MRI safety update 2008: part 1, MRI contrast agentsand nephrogenic systemic fibrosis, AJR Am J Roentgenol, 2008;191(4):1129-1139.
  • Shellock FG, Parker JR, Pirovano G, Shen N, Venetianer C, Kirchin MA, SpinazziA, Safety characteristics of gadobenate dimeglumine: clinical experience fromintra- and interindividual comparison studies with gadopentetate dimeglumine,J Magn Reson Imaging, 2006;24(6):1378-1385.
  • Seeliger E, Flemming B, Wronski T, Ladwig M, Arakelyan K, Godes M, Mockel M,Persson PB, Viscosity of contrast media perturbs renal hemodynamics, J Am SocNephrol, 2007;18(11):2912-2920.
  • Seeliger E, Becker K, Ladwig M, Wronski T, Persson PB, Flemming B, Up to50-fold increase in urine viscosity with iso-osmolar contrast media in therat, Radiology, 2010;256(2):406-414.
  • Sandhu GS, Rezaee RP, Jesberger J, Wright K, Griswold MA, Gulani V, TimeresolvedMR angiography of the legs at 3 T using a low dose of gadolinium:initial experience and contrast dynamics, AJR Am J Roentgenol, 2012;198(3):686-691.
  • Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, DjamaliA, Nephrogenic systemic fibrosis: risk factors and incidence estimation,Radiology, 2007;243(1):148-157.
  • Runge VM, Kenney CM, Phase II double-blind, dose-ranging clinical evaluation ofgadobenate dimeglumine in focal liver lesions: with analysis of liver andkidney signal change on early and delayed imaging., J Magn Reson Imaging,2000;11(6):655-664.
  • Runge VM, Dickey KM, Williams NM, Peng X, Local tissue toxicity in response toextravascular extravasation of magnetic resonance contrast media, InvestRadiol, 2002;37(7):393-398.
  • Rank W, Preventing contrast media-induced nephrotoxicity, Nursing, 2013;43(4):48-51.
  • Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Risk factors for NSF: aliterature review, J Magn Reson Imaging, 2009;30(6):1298-1308.
  • Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapazRL, Lee HJ, Magro CM, Valeri AM, Incidence of nephrogenic systemic fibrosisat two large medical centers, Radiology, 2008;248(3):807-816.
  • Park BJ, Kim MG, Suh SI, Hong SJ, Cho KR, Seo BK, Lee KY, The Usefulness ofTest Bolus Examination in Three-Dimensional Contrast-Enhanced MR Angiographyof the Carotid Artery, J Korean Radiol Soc, 2001;44(3):317-323.
  • Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W, Safety of gadolinium-DTPA: extended clinical experience, Magn Reson Med, 1991;22(2):222-228.
  • Murphy KP, Szopinski KT, Cohan RH, Mermillod B, Ellis JH, Occurrence of adversereactions to gadolinium-based contrast material and management of patients atincreased risk: a survey of the American Society of Neuroradiology FellowshipDirectors, Acad Radiol. 1999;6(11):656-664.
  • Menke J, Carotid MR angiography with traditional bolus timing: clinicalobservations and Fourier-based modelling of contrast kinetics, Eur Radiol,2009;19(11):2654-2662.
  • McCullough PA, Bertrand ME, Brinker JA, Stacul F, A meta-analysis of the renalsafety of isosmolar iodixanol compared with low-osmolar contrast media, J AmColl Cardiol, 2006;48(4):692-699.
  • Mathur-De Vre R, Lemort M, Invited review: biophysical properties and clinicalapplications of magnetic resonance imaging contrast agents, Br J Radiol,1995;68(807):225-247.
  • Masui T, Takehara Y, Aoshima R, Kaneko M, Acute hemodynamic effects ofintravenous bolus injection of ionic and nonionic magnetic resonance contrastmedia, Acad Radiol, 1995;2(2):148-153.
  • Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS,Nephrogenic systemic fibrosis: suspected causative role of gadodiamide usedfor contrast-enhanced magnetic resonance imaging, J Am Soc Nephrol,2006;17(9):2359-2362.
  • Lin SP, Brown JJ, MR contrast agents: physical and pharmacologic basics, J MagnReson Imaging, 2007;25(5):884-899.
  • Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC, Acute adverse reactions tomagnetic resonance contrast media--gadolinium chelates, Br J Radiol,2006;79(941):368-371.
  • Lenhard DC, Pietsch H, Sieber MA, Ernst R, Lengsfeld P, Ellinghaus P, Jost G,The osmolality of nonionic, iodinated contrast agents as an important factorfor renal safety, Invest Radiol, 2012;47(9):503-510.
  • Lee JJ, Chang Y, Kang DS, Contrast-enhanced magnetic resonance angiography:dose the test dose bolus represent the main dose bolus accurately?, Korean JRadiol, 2000;1(2):91-97.
  • Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, NurulainSM, Singh S, Fuchsjager M, In an animal model nephrogenic systemic fibrosiscannot be induced by intraperitoneal injection of high-dose gadolinium basedcontrast agents, Eur J Radiol, 2012;81(10):2562-2567.
  • Korn A, Fenchel M, Hauser TK, Bisdas S, Nagele T, Ernemann U, Klose U, BenderB, Double Bolus Application in TWIST-MR-Angiography of the Cervical Arteries,Radiol Res Pract, 2012;2012:203538.
  • Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP, Assessment ofutilization and pharmacovigilance based on spontaneous adverse eventreporting of gadopentetate dimeglumine as a magnetic resonance contrast agentafter 45 million administrations and 15 years of clinical use, Invest Radiol,2006;41(6):491-499.
  • Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K, Recent topics related tonephrogenic systemic fibrosis associated with gadolinium-based contrastagents, Int J Urol, 2012;19(9):806-811.
  • Kanakia, S.; Toussaint, J. D.; Chowdhury, S. M.; Lalwani, G.; Tembulkar, T.; Button, T.; Shroyer, K. R.; Moore, W.; Sitharaman, B. Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent. Int. J. Nanomedicine 2013, 8, 2821-2833.
  • Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M,Guarner J, Pollack B, Saab G, Patel PR, Gadolinium-containing magneticresonance imaging contrast and nephrogenic systemic fibrosis: a case-controlstudy, Am J Kidney Dis, 2008;51(6):966-975.
  • Jost G, Behrendt FF, Pietsch H, Keil S, Mottaghy FM, Gunther RW, Mahnken AH,Low-osmolar monomeric versus iso-osmolar dimeric contrast media: anintra-individual comparison in CT angiography using an animal model, J MedImaging Radiat Oncol, 2011;55(2):170-175.
  • Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C, Clinical andbiological consequences of transmetallation induced by contrast agents formagnetic resonance imaging: a review, Fundam Clin Pharmacol, 2006;20(6):563-576.
  • Idee JM, Port M, Dencausse A, Lancelot E, Corot C, Involvement of gadoliniumchelates in the mechanism of nephrogenic systemic fibrosis: an update, RadiolClin North Am, 2009;47(5):855-869.
  • Idee JM, Fretellier N, Robic C, Corot C, The role of gadolinium chelates in themechanism of nephrogenic systemic fibrosis: A critical update, Crit RevToxicol, 2014;44(10):895-913.
  • Homayoon B, Diwakar H, Strovski E, Bakshi D, Harris AC, Thoeni RF, Chang SD,Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamicmagnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison, Abdom Imaging, 2014;39(5):955-962.
  • Ho VB, Foo TK, Czum JM, Marcos H, Choyke PL, Knopp MV, Contrast-enhancedmagnetic resonance angiography: technical considerations for optimizedclinical implementation, Top Magn Reson Imaging, 2001;12(4):283-299.
  • Hao D, Ren C, Li C, Revisiting the variation of clustering coefficient ofbiological networks suggests new modular structure, BMC Syst Biol, 2012;6:34.
  • Hany TF, McKinnon GC, Leung DA, Pfammatter T, Debatin JF, Optimization ofcontrast timing for breath-hold three-dimensional MR angiography, J MagnReson Imaging, 1997;7(3):551-556.
  • Haneder S, Kucharczyk W, Schoenberg SO, Michaely HJ, Safety of magneticresonance contrast media: a review with special focus on nephrogenic systemicfibrosis, Top Magn Reson Imaging, 2015;24(1):57-65.
  • Grobner T, Prischl FC, Gadolinium and nephrogenic systemic fibrosis, KidneyInt, 2007;72(3):260-264.
  • Grant CW, Karlik S, Florio E, A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA, Magn Reson Med, 1989;11(2):236-243.
  • Goyen M, Lauenstein TC, Herborn CU, Debatin JF, Bosk S, Ruehm SG, 0.5 M Gdchelate(Magnevist) versus 1.0 M Gd chelate(Gadovist): dose-independent effecton image quality of pelvic three-dimensional MR-angiography, J Magn ResonImaging, 2001;14(5):602-607.
  • Galea N, Francone M, Zaccagna F, Ciolina F, Cannata D, Algeri E, Agati L,Catalano C, Carbone I, Ultra low-dose of gadobenate dimeglumine for lategadolinium enhancement(LGE) imaging in acute myocardial infarction: afeasibility study, Eur J Radiol, 2014;83(12):2151-2158.
  • Forsting M, Palkowitsch P, Prevalence of acute adverse reactions to gadobutrolahighly concentrated macrocyclic gadolinium chelate: review of 14,299patients from observational trials, Eur J Radiol 2010;74(3): 186-192.
  • FDA, FDA Drug Safety Communication: New warnings for using gadolinium-basedcontrast agents in patients with kidney dysfunction, 2010.
  • Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC, Frequency and severity ofacute allergic-like reactions to gadolinium-containing i.v. contrast media inchildren and adults, AJR Am J Roentgenol, 2007;189(6):1533-1538.
  • Deray G, Jacobs C, Are low osmolality contrast media less nephrotoxic?, NephrolDial Transplant, 1996;11(6):930-931.
  • Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE, Scleromyxoedemalikecutaneous diseases in renal-dialysis patients, Lancet, 2000;356(9234):1000-1001.
  • Costa N, Understanding Contrast Media, Journal of Infusion Nursing, 2004;27(5):302-312.
  • Choi J, Lim SM, Kim Y, Comparison of 3D TOF MRA with Contrast Enhanced MRA inIntracranial Atherosclerotic Occlusive Disease, J Korean Radiol Soc,2011;64(3):203-211.
  • Caravan P, Ellison JJ, McMurry TJ, Lauffer RB, Gadolinium(III) Chelates as MRIContrast Agents: Structure, Dynamics, and Applications, Chem Rev, 1999;99(9):2293-2352.
  • Burai L, Hietapelto V, Kiraly R, Toth E, Brucher E, Stability constants and 1Hrelaxation effects of ternary complexes formed between Gd-DTPA, Gd-DTPA-BMA,Gd-DOTA, and Gd-EDTA and citrate, phosphate, and carbonate ions, Magn ResonMed, 1997;38(1):146-150.
  • Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA,Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists shouldbe concerned, AJR Am J Roentgenol, 2007;188(2):586-592.
  • Boyd AS, Wilmoth MC, An innovative community-based intervention for AfricanAmerican women with breast cancer: the Witness Project, Health Soc Work,2006;31(1):77-80.
  • Bousquet JC, Saini S, Stark DD, Hahn PF, Nigam M, Wittenberg J, Ferrucci JT Jr,Gd-DOTA: characterization of a new paramagnetic complex, Radiology,1988;166(3):693-698.
  • Bilecen D, Schulte AC, Heidecker HG, Aschwanden M, Huegli R, Jaeger KA,Ostheim-Dzerowycz W, Bongartz G, Lower extremity: low-dose contrast agentintraarterial MR angiography in patients-initial results, Radiology,2005;234(1):250-255.
  • Bellin MF, Van Der Molen AJ, Extracellular gadolinium-based contrast media: anoverview, Eur J Radiol, 2008;66(2):160-167.
  • Bellin MF, MR contrast agents, the old and the new, Eur J Radiol, 2006;60(3):314-323.
  • Arakelyan K, Cantow K, Hentschel J, Flemming B, Pohlmann A, Ladwig M, NiendorfT, Seeliger E, Early effects of an x-ray contrast medium on renal T(2)*/T(2)MRI as compared to short-term hyperoxia, hypoxia and aortic occlusion inrats, Acta Physiol, 2013;208(2):202-213.
  • Amet S, Launay-Vacher V, Clement O, Frances C, Tricotel A, Stengel B, GauvritJY, Grenier N, Reinhardt G, Janus N, Choukroun G, Laville M, Deray G,Incidence of nephrogenic systemic fibrosis in patients undergoing dialysisafter contrast-enhanced magnetic resonance imaging with gadolinium-basedcontrast agents: the Prospective Fibrose Nephrogenique Systemique study,Invest Radiol, 2014;49(2):109-115.
  • American College of Radiology, Manual on contrast media version 7,http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual/FullManual.aspx, 2010.
  • Altun E, Semelka RC, Cakit C, Nephrogenic systemic fibrosis and management ofhigh-risk patients, Acad Radiol, 2009;16(7):897-905.
  • Alami Z, Nasri S, Ahid S, Kacem HH, Extravasation of contrast medium during CTexamination: an observational case-control study, Pan Afr Med J, 2015;20:89.